O'Shaughnessy J, Sousa S, Cruz J, Fallowfield L, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer 2021;152:223-232.
PMID: 34147014